Search clinical trials for: Valganciclovir

Total 121 results

Cecilia Soderberg-Naucler
Karolinska University Hospital; Karolinska Institutet

Recruiting

A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients (VIGAS2)

Glioblastoma Multiforme

Sweden
University Hospital Birmingham NHS Foundation Trust
National Institute for Health Research, United Kingdom

Completed

Cytomegalovirus Control in Critical Care (CCCC)

Critical Illness

United Kingdom
Luis Eduardo Morales Buenrostro

Completed

Pharmacokinetic Parameters of Innovative Valganciclovir Versus Generic Valganciclovir

Kidney Transplantation | Pharmacokinetics | Cytomegalovirus Infections | Therapeutic Equivalency

Mexico
GenVivo, Inc.

Recruiting

Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors

Solid Tumor, Adult

United States
Stanford University

Completed

Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)

Chronic Fatigue Syndrome

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Weill Medical College of Cornell University; University of North Carolina, Chapel Hill and other collaborators

Completed

Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma

Sarcoma

United States
Rabin Medical Center

Completed

Valganciclovir Dosing in Pediatric Solid Organ Transplant Recipients

Infection in Solid Organ Transplant Recipients

Israel
University of California, San Francisco
Roche Pharma AG

Completed

Valganciclovir to Reduce T Cell Activation in HIV Infection

HIV Infections | Cytomegalovirus Infections

United States
Hoffmann-La Roche

Completed

A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.

Cytomegalovirus Infections

United States
Dr. Reddy's Laboratories Limited

Completed

Bioavailability Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fasting Condition

Healthy

India
Dr. Reddy's Laboratories Limited

Completed

Bioavailability Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fed Condition

Healthy

India
Scott Palmer
Roche Pharma AG

Completed

Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation (Valgan)

Cytomegalovirus Infections

United States
Karolinska Institutet
Karolinska University Hospital

Completed

Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection

Glioblastoma Multiforme | Cytomegalovirus Infection

Sweden
Hoffmann-La Roche

Completed

A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients

Cytomegalovirus Infections

Spain, France, Germany, Mexico, United States, Australia, Canada
University of Washington
Hoffmann-La Roche

Completed

Suppression of Oral HHV8 Shedding With Valganciclovir

Human Herpesvirus 8

United States
Hoffmann-La Roche

Completed

A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age

Cytomegalovirus Infections, Heart Transplantation

Spain, United States, Canada
Viracta Therapeutics, Inc.

Recruiting

An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)

EBV Related Non-Hodgkin's Lymphoma | Epstein-Barr Virus Associated Lymphoproliferative Disorder | EBV-Related PTLD | EBV Associated Lymphoma | EBV-Positive DLBCL, NOS | EBV Related PTCL, NOS

United States, Spain, Italy, United Kingdom, Singapore, Taiwan, Korea, Republic of, Germany, Canada, Brazil, Australia, France, Malaysia, Hong Kong, Israel
Hoffmann-La Roche

Completed

A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients

Kidney Transplantation, Cytomegalovirus Infections

Spain, Mexico, United Kingdom, United States, Australia, Brazil, France, Germany, Sweden
Viracta Therapeutics, Inc.

Recruiting

A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers

Advanced Cancer

Spain
University of Minnesota

Completed

ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation

Epstein-Barr Virus Infections | Cytomegalovirus Infections | Transplantation Infection

United States
Hoffmann-La Roche

Completed

A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation

Cytomegalovirus Infections

Germany, Austria
Assistance Publique - Hôpitaux de Paris

Terminated

Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance (GANCIMVEAR)

Congenital Cytomegalovirus (CMV)

France
Salvador Gil-Vernet
Roche Pharma AG

Completed

Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients

Cytomegalovirus Infection

Spain
New York Medical College

Recruiting

CMV CTLs in Neonates With CMV Infection

Congenital Cytomegaloviral (CMV) Disease

United States
Marcus Saemann

Unknown

Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients (Certi-CMV)

Cytomegalovirus Disease

Austria
National Institute of Allergy and Infectious Diseases...

Terminated

Asymptomatic Congenital CMV Treatment

Congenital Cytomegalovirus Infection

United States
Mayo Clinic
Roche Pharma AG; University of Michigan; University of Florida; Fred Hutchinson... and other collaborators

Completed

The Study is Being Done to See if Taking the Drug Valganciclovir Can Prevent CMV Infection.

Bone Marrow Stem Cell Transplant

United States
Hoffmann-La Roche

Unknown

Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection

HIV Infections | Cytomegalovirus Retinitis

United States, Puerto Rico
University of Pittsburgh
Hoffmann-La Roche

Terminated

WP16302 A Bioequivalence Study Comparing Ganciclovir From the Valganciclovir Syrup Formulation and the Commercial Valganciclovir 450mg Tablet (Valcyte®) at a Dose of 900mg in Kidney Transplant Recipients

Kidney Transplant

United States
PETHEMA Foundation

Completed

TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant

Cytomegalovirus Infection

Spain
Hoffmann-La Roche

Completed

VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients

Cytomegalovirus Infections

Spain, Australia, Ireland, India, Italy, Canada, Belgium, Switzerland, Estonia, Austria, United Kingdom, Brazil, Mexico, Norway, Latvia, Turkey, Croatia, Serbia, Poland, New Zealand, Venezuela
University of Minnesota

Completed

Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients

CMV Viremia | EBV Viremia

United States
National Institute of Allergy and Infectious Diseases...

Completed

Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV

HIV Infections | Cytomegalovirus Infections

United States, Puerto Rico
University Hospital, Grenoble

Terminated

MICI-CMV:Valganciclovir in Recurrent Bouts of Cryptogenic Inflammatory Bowel Diseases With an Infection by Cytomegalovirus

Inflammatory Bowel Diseases | Cytomegalovirus Infections

France
Hoffmann-La Roche

Completed

A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS

HIV Infections | Cytomegalovirus Retinitis

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation

Infection

United States
University of California, San Diego
National Cancer Institute (NCI)

Withdrawn

Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer

Lymphoma | Head and Neck Cancer | Gastric Cancer | Lymphoproliferative Disorder

United States
Hoffmann-La Roche

Completed

IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients (IMPACT)

Cytomegalovirus Infections

United States, Belgium, United Kingdom, Canada, France, Spain, Brazil, Australia, Germany, Italy, Romania, New Zealand, Poland
Medical University of Vienna

Completed

Antiviral Treatment of Chronic Lymphocytic Leukemia (VGCV-CLL)

Chronic Lymphocytic Leukemia

Austria
University Health Network, Toronto

Completed

Cell Mediated Immunity for Secondary Prophylaxis in CMV SOT Patients (Q-CMV)

Cytomegalovirus Viraemia

Canada
National Institute of Allergy and Infectious Diseases...

Completed

CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL")

Cytomegalovirus Infection

United States
National Institutes of Health Clinical Center (CC)

Completed

Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant Recipients

Kidney Trasplant

United States
University of Bologna

Unknown

Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy (PROTECT)

Heart Transplantation | Cytomegalovirus Infection | Cardiac Allograft Vasculopathy

Italy
Piedmont Healthcare
ViraCor Laboratories

Recruiting

Utilization of the Viracor® Assay for Valganciclovir Prophylaxis in CMV High Risk Kidney Transplant Recipients

Kidney Transplant; Complications

United States
University of Washington
Hoffmann-La Roche

Withdrawn

Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease

Giant Lymph Node Hyperplasia
Washington University School of Medicine
Hoffmann-La Roche

Completed

Study of Prophylactic Vs Preemptive Valganciclovir

Cytomegalovirus Infection

United States
Laureate Institute for Brain Research, Inc.

Recruiting

ANTIVIRAL TREATMENT OF CYTOMEGALOVIRUS IN DEPRESSION

Major Depressive Disorder

United States
Heidelberg ImmunoTherapeutics GmbH

Completed

Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 2 Infection (MATCH-2)

Herpes Genitalis

Germany
Oregon Health and Science University

Unknown

Prophylactic Therapy for Cytomegalovirus in Liver Transplant Recipients

Liver Transplantation
Nuria Lloberas
Ministerio de Sanidad, Servicios Sociales e Igualdad

Completed

Individualization of Ganciclovir and Valganciclovir Doses Using Bayesian Prediction in Renal Transplant Patients.

Infection in Solid Organ Transplant Recipients

Spain

Search clinical trials for: Valganciclovir

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations